Adipotide vs Leuprolide
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
AdipotideSexual Health & Libido
Leuprolide- Summary
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Half-Life
- Estimated 2-4 hours
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Admin Route
- Subcutaneous, Intravenous (research)
- SubQ, IM
- Research
- —
- —
- Typical Dose
- Not established for humans; primate studies used 0.1-1 mg/kg
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- Daily for 4 weeks (research protocol)
- Per depot schedule
- Key Benefits
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Side Effects
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Stacks With
- —
- —